The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death - PubMed (original) (raw)
The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death
Ram N Trivedi et al. Cancer Res. 2005.
Abstract
DNA-alkylating agents have a central role in the curative therapy of many human tumors; yet, resistance to these agents limits their effectiveness. The efficacy of the alkylating agent temozolomide has been attributed to the induction of O6-MeG, a DNA lesion repaired by the protein O6-methylguanine-DNA methyltransferase (MGMT). Resistance to temozolomide has been ascribed to elevated levels of MGMT and/or reduced mismatch repair. However, >80% of the DNA lesions induced by temozolomide are N-methylated bases that are recognized by DNA glycosylases and not by MGMT, and so resistance to temozolomide may also be due, in part, to robust base excision repair (BER). We used isogenic cells deficient in the BER enzymes DNA polymerase-beta (pol-beta) and alkyladenine DNA glycosylase (Aag) to determine the role of BER in the cytotoxic effect of temozolomide. Pol-beta-deficient cells were significantly more susceptible to killing by temozolomide than wild-type or Aag-deficient cells, a hypersensitivity likely caused by accumulation of BER intermediates. RNA interference-mediated pol-beta suppression was sufficient to increase temozolomide efficacy, whereas a deficiency in pol-iota or pol-lambda did not increase temozolomide-mediated cytotoxicity. Overexpression of Aag (the initiating BER enzyme) triggered a further increase in temozolomide-induced cytotoxicity. Enhanced Aag expression, coupled with pol-beta knockdown, increased temozolomide efficacy up to 4-fold. Furthermore, loss of pol-beta coupled with temozolomide treatment triggered the phosphorylation of H2AX, indicating the activation of the DNA damage response pathway as a result of unrepaired lesions. Thus, the BER pathway is a major contributor to cellular resistance to temozolomide and its efficacy depends on specific BER gene expression and activity.
Similar articles
- Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide.
Trivedi RN, Wang XH, Jelezcova E, Goellner EM, Tang JB, Sobol RW. Trivedi RN, et al. Mol Pharmacol. 2008 Aug;74(2):505-16. doi: 10.1124/mol.108.045112. Epub 2008 May 13. Mol Pharmacol. 2008. PMID: 18477668 Free PMC article. - Temozolomide: mechanisms of action, repair and resistance.
Zhang J, Stevens MF, Bradshaw TD. Zhang J, et al. Curr Mol Pharmacol. 2012 Jan;5(1):102-14. doi: 10.2174/1874467211205010102. Curr Mol Pharmacol. 2012. PMID: 22122467 - N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR, Sobol RW. Tang JB, et al. Neuro Oncol. 2011 May;13(5):471-86. doi: 10.1093/neuonc/nor011. Epub 2011 Mar 3. Neuro Oncol. 2011. PMID: 21377995 Free PMC article. - BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis.
Kaina B, Ochs K, Grösch S, Fritz G, Lips J, Tomicic M, Dunkern T, Christmann M. Kaina B, et al. Prog Nucleic Acid Res Mol Biol. 2001;68:41-54. doi: 10.1016/s0079-6603(01)68088-7. Prog Nucleic Acid Res Mol Biol. 2001. PMID: 11554312 Review. - Triazene compounds: mechanism of action and related DNA repair systems.
Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Marchesi F, et al. Pharmacol Res. 2007 Oct;56(4):275-87. doi: 10.1016/j.phrs.2007.08.003. Epub 2007 Aug 9. Pharmacol Res. 2007. PMID: 17897837 Review.
Cited by
- Emissive Alkylated Guanine Analogs as Probes for Monitoring O 6-Alkylguanine-DNA-transferase Activity.
Steinbuch KB, Bucardo M, Tor Y. Steinbuch KB, et al. ACS Omega. 2024 Aug 17;9(34):36778-36786. doi: 10.1021/acsomega.4c05700. eCollection 2024 Aug 27. ACS Omega. 2024. PMID: 39220506 Free PMC article. - DNA abasic sites act as rational therapeutic targets to synergize temozolomide response in both MMR-proficient and deficient cancer.
Bora A, Pal R, Mandi CS, Dutta S. Bora A, et al. NAR Cancer. 2024 Jul 25;6(3):zcae034. doi: 10.1093/narcan/zcae034. eCollection 2024 Sep. NAR Cancer. 2024. PMID: 39055333 Free PMC article. Review. - Mouse models to explore the biological and organismic role of DNA polymerase beta.
Sobol RW. Sobol RW. Environ Mol Mutagen. 2024 Apr;65 Suppl 1(Suppl 1):57-71. doi: 10.1002/em.22593. Environ Mol Mutagen. 2024. PMID: 38619421 Review. - Mitochondrial transcription factor A (TFAM) has 5'-deoxyribose phosphate lyase activity in vitro.
Zhao W, Hussen AS, Freudenthal BD, Suo Z, Zhao L. Zhao W, et al. DNA Repair (Amst). 2024 May;137:103666. doi: 10.1016/j.dnarep.2024.103666. Epub 2024 Mar 8. DNA Repair (Amst). 2024. PMID: 38492429 - Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma.
Cheng X, An J, Lou J, Gu Q, Ding W, Droby GN, Wang Y, Wang C, Gao Y, Anand JR, Shelton A, Satterlee AB, Mann B, Hsiao YC, Liu CW, Lu K, Hingtgen S, Wang J, Liu Z, Miller CR, Wu D, Vaziri C, Yang Y. Cheng X, et al. Nat Commun. 2024 Mar 4;15(1):1957. doi: 10.1038/s41467-024-45979-5. Nat Commun. 2024. PMID: 38438348 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials